Date published:
June 15, 2020

Lifecare’s partner Digital Diagnostics AG seeks additional approval in Germany for corona virus rapid test

Plan for scaling capacities with production partners in USA and Europe and aim to bring test to the market in millions.

The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership in Digital Diagnostics AG which has developed an accurate and reliable rapid test able to detect corona virus from the time of infection, contrary to other tests on the market that can only detect the antibodies 5-7 days after the infection. The test is independent of lab analysis, providing test result within minutes at the point-of-care.

Digital Diagnostics announced June 12th, 2020, that the company has applied to the German Federal Institute for Drugs and Medical Devices (BfArM) for approval of the Digid CantisenseTM SARS-CoV-2 test for Germany. This application comes in addition to the previous application to the US FDA, announced June 2de, 2020.

Digital Diagnostics expect approval from BfArM and FDA in the next few weeks, where after the goal is to bring the tests to the market in millions. In the short-term Digital Diagnostics are further scaling its capasities with production partners in the USA and Europe.

For additional background information, we refer to:

Press contact Lifecare

Christian Saure

Chairman of the Board

+47 909 33 148

Other publications

Date published:
July 2, 2021

Information to the shareholders

Read more
Date published:
June 30, 2021

Open Position – Leading Senior Scientist Nanotechnology Development

Read more
Date published:
June 24, 2021

Lifecare AS acquires Cantimed UG and broadens its biosensing capabilities

Read more